Sattar Naveed, Wannamethee Goya, Sarwar Nadeem, Tchernova Julia, Cherry Lynne, Wallace A Michael, Danesh John, Whincup Peter H
University Department of Vascular Biochemistry, Glasgow, Scotland.
Circulation. 2006 Aug 15;114(7):623-9. doi: 10.1161/CIRCULATIONAHA.106.618918. Epub 2006 Aug 7.
There is uncertainty about the association between circulating concentrations of adiponectin and coronary heart disease (CHD) risk. We report new data from a prospective study in the context of a meta-analysis of previously published prospective studies.
We measured baseline adiponectin levels in stored serum samples of 589 men with fatal CHD or nonfatal myocardial infarction and in 1231 controls nested within a prospective study of 5661 men (aged 40 to 59 years) recruited during 1978-1980, as well as in paired samples obtained 4 years apart from 221 of these participants. Baseline adiponectin concentrations correlated (P < 0.0001) positively with HDL cholesterol (r = 0.33) and inversely with C-reactive protein (r = -0.11) and BMI (r = -0.21), and the year-to-year consistency of adiponectin values was comparable to those of blood pressure and total cholesterol levels. No significant difference between median adiponectin levels at baseline was observed between cases and controls (10.2 versus 10.8 microg/mL; P = 0.5), despite the fact that body mass index, HDL, and C-reactive protein were all significant predictors of events in this cohort. The odds ratio for CHD was 0.89 (95% CI, 0.67 to 1.18) in a comparison of men in the top third of adiponectin concentrations compared with those in the bottom third, similar to a meta-analysis (including the present study) of 7 prospective studies involving a total of 1318 CHD cases (odds ratio, 0.84 [95% CI, 0.70 to 1.01]).
In contrast to the strong associations previously reported between adiponectin levels and risk of type 2 diabetes, any association with CHD risk is comparatively moderate and requires further investigation.
脂联素循环浓度与冠心病（CHD）风险之间的关联存在不确定性。我们在对先前发表的前瞻性研究进行荟萃分析的背景下，报告一项前瞻性研究的新数据。
我们测量了589例患有致命性冠心病或非致命性心肌梗死的男性以及1231例对照者（这些对照者来自于1978年至1980年招募的5661例40至59岁男性的前瞻性研究）储存血清样本中的基线脂联素水平，同时也测量了从这些参与者中的221例获取的间隔4年的配对样本中的基线脂联素水平。基线脂联素浓度与高密度脂蛋白胆固醇呈正相关（P < 0.0001，r = 0.33），与C反应蛋白呈负相关（r = -0.11），与体重指数呈负相关（r = -0.21），并且脂联素值的逐年一致性与血压和总胆固醇水平相当。尽管体重指数、高密度脂蛋白和C反应蛋白都是该队列中事件的显著预测因素，但病例组和对照组在基线时脂联素水平中位数无显著差异（10.2对10.8μg/mL；P = 0.5）。与脂联素浓度处于最低三分之一的男性相比，脂联素浓度处于最高三分之一的男性患冠心病的比值比为0.89（95%可信区间，0.67至1.18），这与一项包括本研究在内的涉及总共1318例冠心病病例的7项前瞻性研究的荟萃分析结果相似（比值比，0.84 [95%可信区间，0.70至1.01]）。
与先前报道的脂联素水平与2型糖尿病风险之间的强关联不同，脂联素与冠心病风险的任何关联相对较弱，需要进一步研究。
